Acetylcholinesterase inhibitors: A patent review (2008 present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 8, 2012, Pages 871-886

  Pohanka, Miroslav ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Alzheimer's disease; Carbofuran; Donepezil; Galantamine; Huperzine; Myasthenia gravis; Nerve agents; Pyridostigmine; Rivastigmine; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; ADONEP; CARBAMIC ACID DERIVATIVE; CARBOFURAN; CHOLINESTERASE INHIBITOR; DESMEDIPHAM; DIMETHOATE; DONEPEZIL; EVERTAS; FENOXYCARB; FOSETYL ALUMINUM; GALANTAMINE; HUPERZINE A; HUPERZINE B; METHIOCARB; METRIFONATE; ORGANOPHOSPHATE INSECTICIDE; PHENMEDIPHAM; PIRIMICARB; PROPAMOCARB; RISTIDIC; RIVASTIGMINE; SARIN; SOMAN; TABUN; TACRINE; UNCLASSIFIED DRUG; VASTIGMEX; YASNAL; ZT 1;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CHOLINERGIC SYSTEM; DIARRHEA; DRUG METABOLISM; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; LEG CRAMP; LIVER TOXICITY; MYASTHENIA GRAVIS; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PATENT; PROTEIN EXPRESSION; REVIEW;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; MYASTHENIA GRAVIS; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864213744     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.701620     Document Type: Review

References (114)

1. Wevers A. Localisation of pre- and postsynaptic cholinergic markers in the human brain. Behav Brain Res 2011;221:341-55
2. Boopathy R, Rajesh RV, Darvesh S, Layer PG. Human serum cholinesterase from liver pathological samples exhibit highly elevated aryl acylamidase activity. Clin Chim Acta 2007;380:151-6 (Pubitemid 46498047)
3. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:219-30
4. Nigg HN, Knaak JB. Blood cholinesterases as human biomarkers of organophosphorus pesticide exposure. Rev Environ Contam Toxicol 2000;163:29-111
5. Loewi O. Uber humorale ubertragbarkeit der Hernervenwirkung. I Mitt Pflugers Arch 1921;189:239-42
6. Schifilliti D, Santamaria LB, Rosa G, et al. Cholinergic central system, Alzheimer's disease, and anesthetics liaison: A vicious circle? J Alzheimers Dis 2010;3:35-41
7. Woolf NJ, Butcher LL. Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 2011;221:488-98
8. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br J Pharmacol 2008;154:1558-71
9. Gabrielle P, Jeana M, Lorenza EC. Cytosolic choline acetyltransferase binds specifically to cholinergic plasma membrane of rat brain synaptosomes to generate membrane-bound enzyme. Neurochem Res 2003;28:543-9 (Pubitemid 36314845)
10. Llona I. Synaptic like microvesicles: do they participate in regulated exocytosis? Neurochem Int 1995;27:219-26
11. Dun AR, Rickman C, Duncan RR. The t-SNARE complex: A close up. Cell Mol Neurobiol 2010;30:1321-6
12. Snyder DA, Kelly ML, Woodbury DJ. SNARE complex regulation by phosphorylation. Cell Biochem Biophys 2006;45:111-23 (Pubitemid 43780385)
13. Singh BR. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox Res 2006;9:73-92
14. Millar NS. A review of experimental techniques used for the heterologous expression of nicotinic acetylcholine receptors. Biochem Pharmacol 2009;78:766-76
15. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89:73-120
16. Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci 2012;13:2219-38
17. Pohanka M, Snopkova S, Havlickova K, et al. Macrophage-assisted inflammation and pharmacological regulation of the cholinergic anti-inflammatory pathway. Curr Med Chem 2011;18:539-51
18. Berstein G, Blank JL, Smrcka AV, et al. Reconstitution of agonist-stimulated phoshpatidylinostiol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, Gq/11 and phospholipase C-beta1. J Biol Chem 1992;267:8081-8
19. Falkenburger BH, Jensen JB, Hille B. Kinetics of M1 muscarinic receptor and G protein signaling to phospholipase C in living cells. J Gen Physiol 2010;135:81-97
20. Parker EM, Kameyama K, Higashijima T, Ross EM. Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. J Biol Chem 1991;266:519-27 (Pubitemid 21906154)
21. Hartmann J, Kiewert C, Duysen EG, et al. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 2007;100:1421-9
22. Cygler M, Schrag JD, Sussman JL, et al. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related enzymes. Protein Sci 1993;2:366-82 (Pubitemid 23071285)
23. Silman I, Sussman JL. Acetylcholinesterase: how is structure related to function? Chem Biol Interact 2008;175:3-10
24. Bartolucci C, Haller LA, Jardis U, et al. Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives. J Med Chem 2010;53:745-51
25. Kreienkamp HJ, Weise C, Raba R, et al. Anionic subsites of the catalytic center of acetylcholinesterase from Torpedo and from cobra venom. Proc Natl Acad Sci USA 1991;88:6117-21 (Pubitemid 21914897)
26. Xu T, Colletier JP, Weik M, et al. Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys J 2008;95:2500-11
27. Hotzgrabe U, Kapkova P, Alptuzun V, et al. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 2007;11:161-79 (Pubitemid 46188812)
28. Johnson G, Moore SW. The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem Biophys Res Commun 1999;258:758-62 (Pubitemid 29290343)
29. Andres C, elMourabit M, Stutz C, et al. Are soluble and membrane-bound rat brain acetylcholinesterase different? Neurochem Res 1990;15:1065-72
30. Massoulie J, Anselment A, Bon S, et al. The polymorphism of acetylcholinesterase: Post-translational processing, quaternary associations and localization. Chem Biol Interact 1999;119:29-42 (Pubitemid 29278536)
31. Liao J, Norgaard-Pedersen B, Brodbeck U. Subunit association and glycosylation of acetylcholinesterase from monkey brain. J Neurochem 1993;61:1127-34 (Pubitemid 23241254)
32. Muller TC, Rocha JB, Morsch VM, et al. Antidepressnats inhibit human acetylcholinesterase activity. Biochim Biophys Acta 2002;1587:92-8 (Pubitemid 34493839)
33. Marrs TC. Organophosphate poisoning. Pharmac Ther 1993;58:51-66 (Pubitemid 23227698)
34. Bajgar J. Organophosphates/nerve agents poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 2004;38:151-216
35. O'Reilly DA, Heikens GT. Organophosphate poisoning in a 12-day-old infant: Case report. Ann Trop Paediatr 2011;31:263-7
36. Thiermann H, Steinritz D, Worek F, et al. Atropine maintenance dosage in Acetylcholinesterase inhibitors: A patent review (2008 - present) Expert Opin. Ther. Patents (2012) 22(8) 883 patients with severe organophosphate pesticide poisoning. Toxicol Lett 2011;206:77-83
37. Pohanka M, Novotny L, Pikula J. Metrifonate alters antioxidant levels and caspase activity in cerebral cortex of Wistar rats. Toxicol Mech Methods 2011;21:585-90
38. Darvesh S, Darvesh KV, McDonald RS, et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem 2008;51:4200-12 (Pubitemid 352032444)
39. Nachon F, Carletti E, Worek F, Masson P. Aging mechanism of butyrylcholinesterase inhibited by an N-methyl analogue of tabun: Implications of the trigonal-bipyramidal transition state rearrangement for the phosphorylation or reactivation of cholinesterases. Chem Biol Interact 2010;187:44-8
40. Flaskos J. The developmental neurotoxicity of organophosphorus insecticides insecticides: A direct role for the oxon metabolites. Toxicol Lett 2012;209:86-93
41. Kasagami T, Miyamoto T, Yamamoto I. Activated transformations of organophosphorus insecticides in the case of non-AChE inhibitory oxons. Pest Manag Sci 2002;58:1107-17 (Pubitemid 35252446)
42. Vlcek V, Pohanka M. Environmental aspects of organophosphorus and carbamate pesticides approved for use in the Czech Republic. Chem Listy 2011;105:908-12
43. Bonner MR, Lee WJ, Sandler DA, et al. Occupational exposure to carbofuran and the incidence of cancer in the agricultural health study. Environ Health Perspect 2005;113:285-9 (Pubitemid 40450659)
44. Rai DK, Sharma B. Carbofuran-induced oxidative stress in mammalian brain. Mol Biotechnol 2007;37:66-71 (Pubitemid 350135908)
45. Ben-Dyke R, Sanderson DM, Noakes DN. Acute toxicity data for pesticides. World Rev Pest Control 1970;9:119-27
46. Weill M, Fort P, Leonetti JP. Use of compounds derived from pyrimidinetrione as acetylcholinesterase inhibitors, compositions containing said derivatives, and the uses thereof. US20080269252A1; 2008
47. Weill M, Lutfalla G, Mogensen K, et al. Comparative genomics: Insecticide resistance in mosquito vectors. Nature 2003;423:136-7 (Pubitemid 36569529)
48. Pohanka M. Alzheimer's disease and related neurodegenerative disorders: Implication and counteracting of melatonin. J Appl Biomed 2011;9:185-96
49. Kao PF, Davis DA, Banigan MG, et al. Modulators of cytoskeletal reorganization in CA1 hippocampal neurons show increased expression in patients at mid-stage Alzheimer's disease. PLoS ONE 2010;5:e13337
50. Lei P, Ayton S, Finkelstein DI, et al. Tau protein: Relevance to Parkinson's disease. Int J Biochem Cell Biol 2010;42:1775-8
51. Holthoewer D, Endres K, Schuck F, et al. Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by p-glycoprotein. Neurodegener Dis 2012;10:224-8
52. Winkler E, Kamp F, Scheuring J, et al. Generation of Alzheimer disease-associated Abeta42/43 by gamma-secretase can directly be inhibited by modulation of membrane thickness. J Biol Chem 2012;In press
53. Didic M, Barbeau EJ, Felician O, et al. Which memory system is impaired first in Alzheimer's disease. J Alzheimers Dis 2011;27:11-22
54. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003;64(Suppl 9):7-10
55. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: The relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004;21:453-78 (Pubitemid 38736890)
56. Wallace TL, Porter RH. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011;82:891-903
57. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009;6:86-96
58. Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a one-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2010;11:1765-71
59. Birks J, Harvey RJ. Donepezil for dementia due to Alzheiemer's disease. Cochrane Database Syst Rev 2003;3:CD001190
60. Heydorn WE. Donepezil (E2020): A new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. Expert Opin Investig Drugs 1997;6:1527-35 (Pubitemid 27432489)
61. Mashkovsky MD, Kruglikova-Lvova RP. On the pharmacology of the new alkaloid galantamine. Farmakologia Toxicologia (Moscow) 1951;14:27-30
62. Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Curr Clin Pharmacol 2010;5:115-24
63. Bartolucci C, Perola E, Pilger C, et al. Three dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti-Alzheimer drugs. Proteins 2001;42:182-91 (Pubitemid 32047326)
64. Schilstrom B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007;32:43-53 (Pubitemid 44967783)
65. Naik RS, Hartmann J, Kiewert C, et al. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci 2009;12:79-85
66. Farlow MR, Grossberg GT, Meng X, et al. Rivastigmine transdermal patch and capsule in Alzheimer's disease: Influence of disease stage on response to therapy. Int J Gariatric Psychiatry 2011;26:1236-43
67. Muller T. Rivastigmine in the treatment of patients with Alzheimer's disease. Neuropsychiatr Dis Treat 2007;3:211-18 (Pubitemid 46864060)
68. Gao X, Zheng CY, Yang L, et al. Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. Free Radic Biol Med 2009;46:1454-62
69. Zhang HY, Tang XC. Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells. Neurosci Lett 2000;292:41-4
70. Coleman BR, Ratcliffe RH, Oguntayo SA, et al. [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact 2008;175:387-95
71. Wang BS, Wang H, Wei ZH, et al. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: An updated meta-analysis. J Neural Transm 2009;116:457-65
72. Ha GT, Wong RK, Zhang Y. Huperzine a as potential treatment of Alzheimer's disease: An assessment on chemistry, pharmacology, and clinical studies. Chem Biodivers 2011;8:1189-204
73. Pohanka M, Hrabinova M, Zemek F, et al. Huperzine induces alteration in oxidative balance and antioxidant in a guinea pig model. Neuro Endocrinol Lett 2011;32(Suppl 1):95-100
74. Pohanka M, Zemek F, Bandouchova H, Pikula J. Toxicological scoring of Alzheimer's disease drug huperzine in a guinea pig model. Toxicol Mech Methods 2012;22:231-5
75. Li YX, Zhang RQ, Li CR, Jiang XH. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet 2007;32:183-7 (Pubitemid 351269805)
76. Ma X, Wang H, Xin J, et al. Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of huperzine A. Eur J Pharmacol 2003;461:89-92 (Pubitemid 36174026)
77. Ma X, Tan C, Zhu D, et al. Huperzine A from Huperzia species - an ethnopharmacological review. J Ethnopharmacol 2007;113:15-34 (Pubitemid 47077860)
78. Kostromytska OS, Buss EA. Seasonal phenology and management of Tomarus subtropicus (Coleoptera: Scarabaedae) in St. Augustinegrass J Econ Entomol 2008;101:1847-55
79. Pohanka M, Novotny L, Pikula J. Metrifonate alters antioxidant levels and caspase activity in cerebral cortex of Wistar rats. Toxicol Mech Methods 2011;21:585-90
80. Heining R, Sachse R. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate. Int J Clin Pharmacol Ther 1999;37:456-64 (Pubitemid 29423983)
81. Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomized, double-blind, placebo controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The metrifonate study group. Alzheimer Dis Assoc Disord 2000;14:39-45 (Pubitemid 30142730)
82. Tumiatti V, Minarini A, Bolognesi ML, et al. Tacrine derivatives and Alzheimer's disease. Curr Med Chem 2010;17:1825-38
83. Meng Q, Ru J, Zhang G, et al. Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes. Toxicol Lett 2006;168:140-7
84. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268-354
85. Gupta S, Mohan CG. 3D-pharmacophore model based virtual screening to identify dual-binding site and selective acetylcholinesterase inhibitors. Med Chem Res 2011;20:1422-30
86. Berson A, Knobloch M, Hanan M, et al. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 2008;131:109-19
87. Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:4-14
88. Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzeheimer's disease: A review of recent clinical studies. Curr Alzheimer Res 2010;7:67-73
89. Yan JW, Li YP, Ye WJ, et al. Design, synthesis and evaluation of isaindigotone derivatives as dual inhibitors for acetylcholinesterase and amyloid beta aggregation. Bioorg Med Chem 2012;20:2527-34
90. Luo W, Li YP, He Y, et al. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. Bioorg Med Chem 2011;19:763-70
91. Ali MA, Ismail R, Choon TS, et al. AChE inhibitor: A regio- and stereo-selective 1,3-dipolar cycloaddition for the synthesis of novel substituted 5,6-dimethoxy spiro[5.3 ']-oxindolespiro-[6.3 "]-2,3-dihydro- 1H-inden-1 "-one-7-(substituted aryl)-tetrahydro-1Hpyrrolo[1,2-c][1,3] thiazole. Bioorg Med Chem Lett 2012;22:508-11
92. Ramba A, Bartolini M, Bisi A, et al. The first dual ChE/FAAH inhibitors: new perspectives for Alzheimer's disease? ACS Med Chem Lett 2012;3:182-6
93. Fernandez-Bachiller MI, Perez C, Monjas L, et al. New tacrine-4-oxo-4Hchromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid reducing properties. J Med Chem 2012;55:1303-17
94. Fernandez-Bachiller MI, Perez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, anti-oxidant, and neuroprotective properties. ChemMedChem 2009;4:828-41
95. Pang YP, Brimijoin S. THA analogs useful as cholinesterase inhibitors. US5783584; 1998
96. Iimura Y, Kosasa T. Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts. US6706741; 2004
97. Gant TG, Sarshar S, Shahbaz MM. Indanone inhibitors of acetylcholinesterase. US20100143505A1; 2012
98. Gil AM, Diaz ID, Arrieta LR, et al. Acetylcholinesterase dual inhibitors. US20050148621A1; 2005 Acetylcholinesterase inhibitors: A patent review (2008 - present) Expert Opin. Ther. Patents (2012) 22(8)
99. Rupniak NMJ, White JF, Shiosaki K, et al. Compounds that inhibit cholinesterase. US20080261950A1; 2008
100. Watterson DM, Eldik LV, Hu W. Composition and treatments using pyridazine compounds and cholinesterase inhibitors. US20090197885A1; 2009
101. Gannon K, Shacham S. Combinations comprising 5HT6 modulators and cholinesterase inhibitors. US2010/ 0152141A1; 2010
102. King MV, Sleight AJ, Woolley ML, et al.. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004;47:195-204 (Pubitemid 38824643)
103. Du S, Andersen MW, Kochinski A. Compositions of cholinesterase inhibitors. US20100256229A1; 2010
104. Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, et al. Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 2007;6:373-8 (Pubitemid 46824097)
105. Argov Z, McKee D, Agus S, et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 2007;69:699-700 (Pubitemid 47256014)
106. Hampton T. Novel therapies target myasthenia gravis. JAMA 2007;298:163-4 (Pubitemid 47057783)
107. Kaminsky HJ. Restoring balance at the neuromuscular junction. Neurology 2007;69:629-30
108. Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2011;2:CD006986
109. Punga AR, Flink R, Askmark H, Stalberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006;34:111-15
110. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig 2011;31:691-701
111. Punga AR, Stalberg E. Acetylcholinesterase inhibitors in MG: To be or not to be? Muscle Nerve 2009;39:724-8
112. Sussman JD, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: Experience with monarsen. Ann N Y Acad Sci 2008;1132:283-90 (Pubitemid 351841365)
113. Brenner T, Hamra-Amitay Y, Evron T, et al. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003;17:214-22 (Pubitemid 36164391)
114. Loewenstein-Lichtenstein Y, Scharz M, Glick D, et al. Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers. Nat Med 1995;1:1082-5